{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:07:52Z","timestamp":1768734472064,"version":"3.49.0"},"reference-count":46,"publisher":"AACN Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:p>Intracerebral hemorrhage is a major source of morbidity and mortality, accounting for 10% of all strokes. Oral anticoagulation therapy, while necessary to prevent thromboembolic complications, increases the risk of intracerebral hemorrhage and can potentially worsen bleeding in cases of acute hemorrhage. Before the introduction of direct oral anticoagulant agents in 2010, warfarin was the only option for oral anticoagulation. These new agents have an improved safety profile compared with warfarin but require different reversal strategies. Anticoagulation reversal in the setting of acute intracerebral hemorrhage is an evolving field. This article covers the most common direct oral anticoagulant medications, various available anticoagulant reversal strategies, and the latest guidelines for anticoagulation reversal in patients with acute intracranial hemorrhage.<\/jats:p>","DOI":"10.4037\/ccn2019160","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T13:15:16Z","timestamp":1559394916000},"page":"e1-e8","source":"Crossref","is-referenced-by-count":3,"title":["Reversing Direct Oral Anticoagulants in Acute Intracranial Hemorrhage"],"prefix":"10.4037","volume":"39","author":[{"given":"Melissa A.","family":"Nestor","sequence":"first","affiliation":[{"name":"Melissa A. Nestor is a neurosciences critical care pharmacist at the University of Kentucky, Lexington, Kentucky, with research interests in sepsis, neurologic injury, and ischemic stroke; Bryan Boling is an advanced practice provider with the Department of Anesthesiology, Division of Critical Care at the University of Kentucky."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Boling","sequence":"additional","affiliation":[{"name":"Melissa A. Nestor is a neurosciences critical care pharmacist at the University of Kentucky, Lexington, Kentucky, with research interests in sepsis, neurologic injury, and ischemic stroke; Bryan Boling is an advanced practice provider with the Department of Anesthesiology, Division of Critical Care at the University of Kentucky."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2471","reference":[{"issue":"10","key":"2019112612214735400_b1-03900e1","first-page":"e146","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association [published corrections appear in Circulation. 2017;135(10): e646 and Circulation. 2017;136(10):e196]","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"issue":"8","key":"2019112612214735400_b2-03900e1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"2019112612214735400_b3-03900e1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jth.12969","article-title":"Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH","volume":"13","author":"Barnes","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2019112612214735400_b4-03900e1","volume-title":"Savaysa [package insert]","year":"2015"},{"key":"2019112612214735400_b5-03900e1","volume-title":"Xarelto [package insert]","year":"2016"},{"key":"2019112612214735400_b6-03900e1","volume-title":"Eliquis [package insert]","year":"2016"},{"key":"2019112612214735400_b7-03900e1","volume-title":"Pradaxa [package insert]","year":"2015"},{"issue":"6","key":"2019112612214735400_b8-03900e1","doi-asserted-by":"crossref","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"2019112612214735400_b9-03900e1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"2019112612214735400_b10-03900e1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"24","key":"2019112612214735400_b11-03900e1","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2019112612214735400_b12-03900e1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11239-015-1314-3","article-title":"Pharmacology of anticoagulants used in the treatment of venous thromboembolism [published correction appears in J Thromb Thrombolysis. 2016;42(2):296-311]","volume":"41","author":"Nutescu","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2019112612214735400_b13-03900e1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2019112612214735400_b14-03900e1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2019112612214735400_b15-03900e1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"issue":"3","key":"2019112612214735400_b16-03900e1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Hemost"},{"issue":"6","key":"2019112612214735400_b17-03900e1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/01.WNL.0000138428.40673.83","article-title":"Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage","volume":"63","author":"Flibotte","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"2019112612214735400_b18-03900e1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"issue":"18","key":"2019112612214735400_b19-03900e1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0000000000003886","article-title":"Outcome of intracerebral hemorrhage associated with different oral anticoagulants [published correction appears in Neurology. 2018;90(23):1084]","volume":"88","author":"Wilson","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"2019112612214735400_b20-03900e1","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1097\/CCM.0000000000002057","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. A statement for healthcare professionals from the Neurocritical Care Society and the Society of Critical Care Medicine","volume":"44","author":"Frontera","year":"2016","journal-title":"Crit Care Med"},{"issue":"22","key":"2019112612214735400_b21-03900e1","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.V114.22.1065.1065","article-title":"Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro","volume":"114","author":"van Ryn","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019112612214735400_b22-03900e1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40256-013-0055-y","article-title":"Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects","volume":"14","author":"Wang","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"issue":"8","key":"2019112612214735400_b23-03900e1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1161\/ATVBAHA.114.303402","article-title":"Antidotes for novel oral anticoagulants: current status and future potential","volume":"35","author":"Crowther","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"2019112612214735400_b24-03900e1","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2215\/CJN.01570213","article-title":"Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience","volume":"8","author":"Singh","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2019112612214735400_b25-03900e1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/15563650.2015.1004580","article-title":"Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran","volume":"53","author":"Bouchard","year":"2015","journal-title":"Clin Toxicol (Phila)"},{"issue":"2","key":"2019112612214735400_b26-03900e1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"issue":"14","key":"2019112612214735400_b27-03900e1","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"2019112612214735400_b28-03900e1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.thromres.2015.07.001","article-title":"Intracranial haemorrhage in patients treated with direct oral anticoagulants","volume":"136","author":"Beynon","year":"2015","journal-title":"Thromb Res"},{"key":"2019112612214735400_b29-03900e1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-017-0158-9","article-title":"Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial","volume":"16","author":"Schenk","year":"2018","journal-title":"Thromb J"},{"issue":"1","key":"2019112612214735400_b30-03900e1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.25134","article-title":"Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage","volume":"83","author":"Gerner","year":"2018","journal-title":"Ann Neurol"},{"issue":"18","key":"2019112612214735400_b31-03900e1","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019112612214735400_b32-03900e1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2019112612214735400_b33-03900e1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.wneu.2017.10.043","article-title":"Safe burr hole surgery for chronic subdural hematoma using dabigatran with idarucizumab","volume":"109","author":"Arai","year":"2018","journal-title":"World Neurosurg"},{"issue":"4","key":"2019112612214735400_b34-03900e1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5811\/cpcem.2017.6.34356","article-title":"Reversal of dabigatran with idarucizumab in acute subarachnoid hemorrhage","volume":"1","author":"Balakumar","year":"2017","journal-title":"Clinical Pract Cases Emerg Med"},{"key":"2019112612214735400_b35-03900e1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tcr.2017.12.003","article-title":"Use of idarucizumab for dabig-atran reversal: emergency department experience in two cases with subdural haematoma","volume":"13","author":"Edwards","year":"2017","journal-title":"Trauma Case Rep"},{"issue":"2","key":"2019112612214735400_b36-03900e1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH16-05-0385","article-title":"Idarucizumab does not have pro-coagulant effects: assessment of thrombosis biomarkers in healthy volunteers","volume":"117","author":"Schmohl","year":"2017","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019112612214735400_b37-03900e1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"issue":"12","key":"2019112612214735400_b38-03900e1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"2019112612214735400_b39-03900e1","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2019112612214735400_b40-03900e1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40265-018-0940-4","article-title":"Andexanet alfa: first global approval [published correction appears in Drugs. 2018;78(12):1285]","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"2019112612214735400_b41-03900e1","volume-title":"Andexxa [package insert]","year":"2018"},{"issue":"2","key":"2019112612214735400_b42-03900e1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb Hae-most"},{"key":"2019112612214735400_b43-03900e1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2016.07.008","article-title":"Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin","volume":"146","author":"Ansell","year":"2016","journal-title":"Thromb Res"},{"issue":"10135","key":"2019112612214735400_b44-03900e1","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(18)31033-X","article-title":"Tranexamic acid for hyperacute primary intracerebral haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial","volume":"391","author":"Sprigg","year":"2018","journal-title":"Lancet"},{"key":"2019112612214735400_b45-03900e1","unstructured":"Treatment of intracerebral hemorrhage in patients on non-vitamin K antagonist (TICH-NOAC). ClinicalTrials.gov website. https:\/\/ClinicalTrials.gov\/show\/NCT02866838. Published August 15, 2016. Updated February 15, 2018. Accessed February 7, 2019."},{"issue":"6","key":"2019112612214735400_b46-03900e1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Critical Care Nurse"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/aacnjournals.org\/ccnonline\/article-pdf\/39\/3\/e1\/119150\/e1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/aacnjournals.org\/ccnonline\/article-pdf\/39\/3\/e1\/119150\/e1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T17:52:06Z","timestamp":1574790726000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacnjournals.org\/ccnonline\/article\/39\/3\/e1\/22053\/Reversing-Direct-Oral-Anticoagulants-in-Acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.4037\/ccn2019160","relation":{},"ISSN":["0279-5442","1940-8250"],"issn-type":[{"value":"0279-5442","type":"print"},{"value":"1940-8250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}